Current stock page

Financial Data

TNDM Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - DevicesScore data as of Nov 18, 2026

TNDMTandem Diabetes Care, Inc.

Healthcare / Medical - Devices

Low Priority

In Line With Peers

NeutralEdge 5/10
$17.05−$0.01 (−0.06%)

Latest quote

  • Momentum
    59
  • Value
    64
  • Quality
    51
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Latest Quarter at a Glance

Quarter ended Sep 30, 2026, compared with the same quarter a year earlier.

Revenue
$283.69M
+13.8% YoY
Net income
-$7.09M
+66.5% YoY
Free cash flow
-$5.51M
−232.0% YoY
Operating margin
-0.8%
+7.2 pts YoY

Quarterly Financial Statements

Updated Nov 19, 2026.

TNDM, last 8 quarters. YoY compares the latest quarter with the same quarter a year earlier.

Income statement
Income statement, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Revenue+13.8%$284M$255M$247M$290M$249M$241M$234M$283M
Gross profit+19.5%$160M$145M$137M$167M$134M$126M$118M$157M
Operating income+88.2%−$2M−$14M−$17M$8M−$20M−$52M−$121M−$582K
Net income+66.5%−$7M−$21M−$20M−$589K−$21M−$52M−$131M$755K
EPS (diluted)+67.7%−$0.10−$0.31−$0.30−$0.01−$0.31−$0.78−$1.97$0.01
Gross margin+2.7 pts56.5%56.9%55.3%57.7%53.9%52.3%50.5%55.7%
Operating margin+7.2 pts-0.8%-5.4%-7.1%2.9%-8.0%-21.5%-51.6%-0.2%
Net margin+6.0 pts-2.5%-8.3%-8.2%-0.2%-8.5%-21.8%-55.7%0.3%
Cash flow
Cash flow, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Operating cash flow−109.9%−$819K−$35M$11M$10M$8M−$9M−$18M$11M
Capital expenditure−14.5%−$5M−$4M−$6M−$7M−$4M−$6M−$3M−$3M
Free cash flow−232.0%−$6M−$39M$5M$3M$4M−$16M−$21M$8M
Free cash flow margin−3.6 pts-1.9%-15.2%1.9%1.1%1.7%-6.5%-9.1%2.7%
Balance sheet
Balance sheet, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Total assets+32.6%$1.16B$1.15B$1.15B$881M$875M$876M$922M$968M
Total liabilities+38.1%$1.02B$1.02B$1.02B$726M$742M$742M$767M$705M
Shareholders' equity+1.6%$135M$130M$132M$155M$133M$133M$155M$263M
Total debt+63.9%$737M$739M$735M$564M$449M$449M$493M$474M
Cash and equivalents−20.8%$73M$63M$179M$91M$92M$64M$54M$69M
Valuation and ratios
Valuation and ratios, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
P/B ratio+1.948.729.869.548.126.787.247.218.45
Return on equity+116.5 pts-36.4%-48.6%-71.4%-131.9%-152.9%-154.1%-118.4%-36.5%
Debt to equity+2.075.455.675.553.643.383.373.181.80
Free cash flow yield−0.3 pts-3.1%-2.1%-0.3%-2.4%-2.8%-0.8%-0.3%0.2%

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
P/E ratio-23.74x
P/B ratio8.8x
Revenue growth (YoY)13.82%
EPS growth (YoY)67.74%
Gross margin56.65%
Operating margin-2.35%
ROE-35.61%
ROIC-2.74%
Debt to equity5.45
FCF yield-3.05%

As of Nov 18, 2026

Technical indicators
MetricValue
Close
As of Nov 18, 2026
$17.05
Volume
As of Nov 13, 2026
4.4M
RSI (14)
As of Nov 13, 2026
59.69
MACD
As of Nov 13, 2026
0.37
MACD signal
As of Nov 13, 2026
0.29
MACD histogram
As of Nov 13, 2026
0.07
ADX (14)
As of Nov 13, 2026
16.54
SMA (50)
As of Nov 13, 2026
$17.40
SMA (200)
As of Nov 13, 2026
$18.84
ATR (14)
As of Nov 13, 2026
$1.39
Historical volatility (annualized)
As of Nov 13, 2026
87.73%
Volume (20-day average)
As of Nov 13, 2026
2.73M
Risk measures
MetricValue
Resilience score38/100
Beta1.07
Annual volatility75.74%
Max drawdown-54.64%
Sharpe ratio0.49
VaR (95%, 1-day)-6.14%

As of Nov 18, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

TNDM Financial Data FAQ

What is Tandem Diabetes Care, Inc.'s revenue?

Tandem Diabetes Care, Inc.'s revenue is one of the core financial data points for TNDM. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Tandem Diabetes Care, Inc.'s revenue growing?

Revenue growth shows whether Tandem Diabetes Care, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is TNDM's EPS?

TNDM's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Tandem Diabetes Care, Inc.'s net income?

Tandem Diabetes Care, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Tandem Diabetes Care, Inc. generate?

Free cash flow shows how much cash Tandem Diabetes Care, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Tandem Diabetes Care, Inc. have?

Cash and debt help frame TNDM's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.